These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1387 related articles for article (PubMed ID: 31009046)
1. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046 [TBL] [Abstract][Full Text] [Related]
2. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]
3. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. Devous MD; Fleisher AS; Pontecorvo MJ; Lu M; Siderowf A; Navitsky M; Kennedy I; Southekal S; Harris TS; Mintun MA J Alzheimers Dis; 2021; 80(3):1091-1104. PubMed ID: 33682705 [TBL] [Abstract][Full Text] [Related]
4. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR; JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304 [TBL] [Abstract][Full Text] [Related]
5. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease. Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800 [TBL] [Abstract][Full Text] [Related]
7. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675 [TBL] [Abstract][Full Text] [Related]
8. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease. Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631 [TBL] [Abstract][Full Text] [Related]
9. Alzheimer's pathology targets distinct memory networks in the ageing brain. Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481 [TBL] [Abstract][Full Text] [Related]
10. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829 [TBL] [Abstract][Full Text] [Related]
11. Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. Cho H; Choi JY; Lee HS; Lee JH; Ryu YH; Lee MS; Jack CR; Lyoo CH J Nucl Med; 2019 Nov; 60(11):1611-1621. PubMed ID: 30926651 [TBL] [Abstract][Full Text] [Related]
12. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956 [TBL] [Abstract][Full Text] [Related]
14. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318 [TBL] [Abstract][Full Text] [Related]
15. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Schumacher J; Gunter JL; Przybelski SA; Jones DT; Graff-Radford J; Savica R; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Knopman DS; Fields JA; Kremers WK; Petersen RC; Graff-Radford NR; Ferman TJ; Boeve BF; Thomas AJ; Taylor JP; Kantarci K Brain; 2021 Nov; 144(10):3212-3225. PubMed ID: 34114602 [TBL] [Abstract][Full Text] [Related]